Highlights and Quick Summary
- Net Aquisitions for the quarter ending September 29, 2019 was $-36 Million (a -70.0% decrease compared to previous quarter)
- Year-over-year quarterly Net Aquisitions decreased by -81.54%
- Annual Net Aquisitions for 2018 was $-736 Million (a 138.96% increase from previous year)
- Annual Net Aquisitions for 2017 was $-308 Million (a -88.83% decrease from previous year)
- Annual Net Aquisitions for 2016 was $-2.76 Billion (a -77.86% decrease from previous year)
- Twelve month Net Aquisitions ending September 29, 2019 was $-671 Million (a -13.42% decrease compared to previous quarter)
- Twelve month trailing Net Aquisitions decreased by -8.83% year-over-year
Trailing Net Aquisitions for the last four month:
|29 Sep '19||29 Jun '19||30 Mar '19||30 Dec '18|
|$-671 Million||$-775 Million||$-684 Million||$-736 Million|
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Net Aquisitions of AbbVie Inc.Most recent Net Aquisitionsof ABBV including historical data for past 10 years.
Interactive Chart of Net Aquisitions of AbbVie Inc.
AbbVie Inc. Net Aquisitions for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Business Profile of AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.